CA2156719A1 - Recombinant epstein-barr virus protein and its use in vaccine - Google Patents
Recombinant epstein-barr virus protein and its use in vaccineInfo
- Publication number
- CA2156719A1 CA2156719A1 CA002156719A CA2156719A CA2156719A1 CA 2156719 A1 CA2156719 A1 CA 2156719A1 CA 002156719 A CA002156719 A CA 002156719A CA 2156719 A CA2156719 A CA 2156719A CA 2156719 A1 CA2156719 A1 CA 2156719A1
- Authority
- CA
- Canada
- Prior art keywords
- ebv
- polypeptide
- protein
- mammal
- admixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 38
- 108700010919 epstein-barr-virus proteins Proteins 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 106
- 229920001184 polypeptide Polymers 0.000 claims abstract description 88
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 88
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004473 Threonine Substances 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 119
- 102000004169 proteins and genes Human genes 0.000 claims description 99
- 210000004027 cell Anatomy 0.000 claims description 72
- 150000007523 nucleic acids Chemical group 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 18
- 241000238631 Hexapoda Species 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 12
- 230000002163 immunogen Effects 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 241000701447 unidentified baculovirus Species 0.000 claims description 9
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 12
- 238000003306 harvesting Methods 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract description 50
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 84
- 229940024606 amino acid Drugs 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 239000013598 vector Substances 0.000 description 15
- 240000000233 Melia azedarach Species 0.000 description 8
- 239000000969 carrier Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010036939 Occlusion Body Matrix Proteins Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000370685 Arge Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- SZRPVOFXFLWAPX-UHFFFAOYSA-K P(=O)([O-])([O-])O.[Ca+2].[Cl-].[Rb+] Chemical compound P(=O)([O-])([O-])O.[Ca+2].[Cl-].[Rb+] SZRPVOFXFLWAPX-UHFFFAOYSA-K 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides recombinant polypeptides based on the 66 kd serine- and threonine-rich portion of gp350/220 of EBV
and the recombinant polypeptide gp350/220. Such polypeptides are useful as vaccines effective against Epstein-Barr virus (EBV) infection.
and the recombinant polypeptide gp350/220. Such polypeptides are useful as vaccines effective against Epstein-Barr virus (EBV) infection.
Description
~ WO94/20138 t 2 1 ~ 6 ~ ~ 9 PCT~S94/02637 RECOMBINANT EPSTEIN-BARR VIRUS PROTEIN
AND ITS USE IN VACCINE
DESCRIPTION
TECHNICAL FIELD
The present invention relates generally to the production of vaccines, specifically to vaccines effective against Epstein-Barr virus (EBV) infection based on the gp350/220 of EBV and on a 66 kd serine- and threonine-rich portion of gp350/220 of EBV.
BACKGROUND ART
Epstein-Barr virus (EBV) is a member of the herpesvirus family which infects most hllm~nc The manifestations of primary infection in normal hllm~nc range from insignificant illness to infectious mononucleosis (Roberts, G.B., Diaqnosis and Clinical Testinq 27, 16-21, 1989). Persistent or latent EBV
infection is an important etiologic factor in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV is an opportunistic pathogen often developing in immnnosuppressed patients who have allografts or in patients with acquired ;mmnne deficiency syndrome (AIDS).
EBV has also been implicated in rheumatoid arthritis and chronic fatigue syndrome. Because of the associated morbidity and mortality, prevention of EBV infection is desirable.
Because EBV does not replicate well in vitro, a systematic approach to selection and production of avirulent virus for preventive ;mmlln;zation is not WO94/20138 Z~S6~ ~ PCT~S94/02637 ~
feasible. Since EBV causes lymphocyte proliferation and is a presumed etiological agent of human malignancies, it is very important that virus preparations used for ;mml~nization be free of potential transforming genes.
For this reason, effective vaccines based on isolated proteins presented on the outer surface of the EBV virus and/or of EBV-infected cells are desirable.
Recombinant proteins provide several advantages over those purified from m~mm~lian tissues infected with the virus. For example, they can be readily produced in large quantities and at high purity. Especially valuable would be vaccines capable not only of neutralizing EBV
virus post-infection, but also to prevent viral binding and entry into B-cells.
Brief Description of the Background Art The principal components of the outer surface of EBV are glycoproteins of 350, 220 and 85 kilodaltons (Pearson, G.R. and Luka, J. In: M.A. Epstein and B.G.
Achong (Eds), The Epstein-Barr Virus. Recent Advances, pp. 48-73. William He;n~m~nn Medical Books, London.) These glycoproteins are also present on the outer surface of infected cell in which the virus is replicating.
Polyclonal and monoclonal antibodies directed against these proteins react with the surface of productively infected cells and neutralize the virus (ibid.).
However, target membrane antigens for antibody-dependent cellular cytotoxicity (ADCC) appeared to be associated with gp350 and gp220 but not with gp85 (ibid.). The EBV
gp350/220 has also been identified as the ligand that m~ tes attachment of the virus to receptor CR2 of human B lymphocytes (Nemerow, G.R., et al., J. Virol. 61, 1416-1420, 1987). The sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu, which corresponds to the N-t~rm;nllc region of gp350/220, has been found to be the epitope responsible W094/20138 ~ 71 9 PCT~S94/OZ~7 for attachment (Nemerow, G.R., et al., Cell 56, 369-377, 1989).
The gp350 and gp220 proteins are encoded by 3.2 and 2.5 kb RNAs which map to the same DNA fragment (~eisel, C., et al., J. Virol. 54, 665-674, 1985).
Antisera raised in rabbits against the gp350/220 protein expressed in E. coli specifically 1mml~noprecipitate gp350 and gp220, react with the plasma membrane of infected cells, and neutralize virus, particularly after the addition of complement. However, multiple injections of substantial quantities of protein are necessary to elicit an effective response. The poor 1mm~nogenicity of gp350/220 expressed in E. coli may be attributable to the absence of glycosylation and proper folding. When expressed in m~mm~lian cells, gp350/220 is highly immunogenic and elicits virus-neutralizing antibodies (Whang, Y., et al., J. Virol. 61, 1796-1807, 1987), indicating that glycosylation plays an important role in the immunogenicity of the glycoprotein. However, the expression of recombinant gp350/220 in m~mm~lian cells is generally very unstable.
Several features of the proteins have been predicted from the DNA and mRNA nucleotide sequence (Beisel, C., et al., J. Virol. 54, 665). The primary translation product of gp350 is a 907 amino acid polypeptide, while that of gp220 is a 710 amino acid polypeptide. At the amino t~rm;nllc of both proteins is an 18-amino acid region which is likely to be a cleavable signal peptide. A single hydrophobic domain which likely functions as a tr~nsm~mhrane anchor is located 26 amino acids from the carboxy terminus of both proteins. The 850 amino acids of gp350 and the 652 amino acids of gp220 between the putative signal and anchor sequences are serine- and threonine-rich and contain 35 (gp350) or 24 (gp220) asparagine-X-serine or -C-threonine sequences, WO94120138 21~ PCT~S94/02637 respectively, which serve as potential signals for N-linked glycosylation. These regions are therefore likely to be present on the outer surface of the membrane.
BRIEF SUMMARY OF THE lN V~N'l'lON
The present invention provides recombinant polypeptides based on the 66 kd serine- and threonine-rich portion of gp350/220 and fragments thereof which are useful as vaccines capable of eliciting EBV-neutralizing antibodies in m~mm~l ian subjects. Preferably, these polypeptides further incorporate a sequence encoding a nine amino acid peptide sequence, Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu, which is involved in mediating EBV
attachment to human B-cells. Vaccines based on polypeptides comprising both the 66 kd polypeptide and this nonamer peptide are also capable of inhibiting viral binding and entry into B-cells.
Accordingly, one aspect of the present invention is a substantially pure polypeptide consisting essentially of the 66 kd serine- and threonine- rich portion of gp350/220 of the Epstein-Barr virus or fragments thereof capable of eliciting EBV-neutralizing antibodies in a m~mm~ 1, Another aspect of the present invention is a substantially pure polypeptide comprising the 66 kd serine- and threonine- rich portion of gp350/220 of the Epstein-Barr virus or fragments thereof and the peptide sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu capable of eliciting EBV-neutralizing antibodieg in a m~mm~l, Such polypeptides are preferentially glycosylated.
Also embraced by the present invention are nucleic sequence encoding these polypeptides and expression vectors comprising such nucleic acids and WO94/20138 21 ~6 ~ PCT~S94/02637 expression control sequences that are operably linked to the nucleic acid and effective in directing expression of said nucleic acid in a cell. A further aspect of the invention is a cell containing such an expression vector as well as methods of producing the polypeptides of the present invention comprising growing such a cell under conditions that permit the production of the polypeptide.
Another aspect of the invention is a vaccine composition comprising an ;mmllnogenic amount of a polypeptide of the present invention admixed with a pharmaceutically acceptable carrier. The inventlon further embraces a method of protecting a m~mm~ 1 from EBV
infection comprising ~mintstering to said m~m~l an immunologically effective dose of such a vaccine composition.
Still another aspect of the invention is a method of producing a su~stantially pure EBV gp350/220 protein, said method comprising subcloning the complete EBV gp350/220 gene into the baculovirus expression vector pBlueBacHisC to form a plasmid pBac-TTI350 which comprises the EBV gp350/220 gene and a 6-histidine peptide gene. This plasmid is used to replace a viral gene encoding the EBV gp350/220 protein and the 6-histidine polypeptide. Then insect cells are transfected with the virus comprising these genes. ~ater the transfected insect cells are harvested and the recombinant EBV gp350/220 protein is ~eparated from the transfected insect cells. Then the EBV gp350/220 protein is puri~ied on a column whose resin has an affinity for a 6-histidine peptide. Another aspect of the present invention is the protein produced by this method.
DETAILED DESCRIPTION QF THE lNv~NllON
The present invention provides recombinant 35 polypcptides based on the EBV gp350/220 protein and on WO94/20138 21~ ~ ~ 19 PCT~S94/02637 ~
the 66 kd serine- and threonine-rich portion o~ gp350/220 which are 1mmllnoreactive with both the EBV imml~ne human serum and a monoclonal antibody that neutralizes EBV
virus. Also provided are polypeptides which further incorporate a sequence encoding a peptide sequence involved in mediating EBV attachment to human B-cells.
Vaccines based on such polypeptides are capable not only of eliciting the production of neutralizing antibodie~
against EBV but also of inhibiting viral binding and entry into B-cells.
Polype~tides The term "gp350/220" refers to the 350 kd and 220 kd outer membrane glycoproteins of Epstein-Barr virus (EBV) which are also present on the ouser surface of infected cells in which EBV is replica~ing. The term also embraces variants or fragments of gp350/220.
The term "66 kd protein" refers to the serine-and threonine- rich portion of gp350/220, encoded by the NcoI fragment of the DNA fragment cont~; n ing the complete EBV gp350/220 coding ~om~;n represented by base pairs numbered 1361-2292 from the initiation codon of the EBV
gp350/220 DNA coding ~om~ln. (Beisel, C., et al., J.
Virol. 54, 665) The term also embraces variants or fragments of the 66 kd protein. Preferably such polypeptides also comprise a peptide sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu, which is involved in mediating EBV attachment to human B-cell receptor CR2.
This nine-amino acid sequence is generally introduced at the amino- or carboxy-tprm;nl~s of the 66 kd protein, most preferably at the amino-t~rm;n-lc.
For the sake of convenience, the term "66 kd protein" as used herein al~o refers to polypeptides comprising the 66 kd polypeptide and this nine amino acid peptide. Only such polypeptides as are capable o~
-WO 94/20L~8 ,~ f~ 71~ PCTIUS94/02637 eliciting EBV-neutralizing antibodies in a human subject are considered to be within the scope of the present invention.
An "-mml~nologically effective dose" of such a 5 polypeptide is an amount capable of eliciting EBV-neutralizing antibodies in a human subject.
Ordinarily, the proteins of the present invention will be at least about 50~ homologous to the 66 kd protein sequence, preferably in excess of about 90~, 10 and, more preferably, at least about 95~ homologous.
Also included are proteins encoded by DNA which hybridize under high or low stringency conditions, to nucleic acids encoding the 66 kd protein, as well as closely related polypeptides or proteins retrieved by antisera to the 66 15 kd protein.
The length of polypeptide sequences compared for homology will generally be at least about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 20 residues, and preferably more than about 35 residues.
~ ubstantial homoloqy or identity The tenn ~Isubstantial homology~ or llsubstantial identity", when referring to polypeptides, indicates that the polypeptide or protein in question exhibits at least about 30~
25 identity with an entire naturally occurring protein or a portion thereof, usually at least about 70~ identity, and preferably at least about 95~ identity.
Homology, for polypeptides, is typically measured using sequence analysis software. See, e.g., 30 Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wisconsin 53705.
Protein analysis software matches similar sequences using measure of homology assigned to various substitutions, 35 deletions, substitutions, and other modifications.
W094/20138 2 ~S~ PCT~S94/02637 Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glut~m'n~; serine, threonine;
lysine, arginine; and phenylalanine, tyrosine.
A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9 to 13 amino acids, and, in various embodiments, at least about 17 or more amino acids.
The polypeptides of the present invention are generally soluble, but the polypeptide also can be coupled to a solid phase support. Many such supports are well known in the art.
"Isolated" The terms "isolated,"
"substantially pure," and "substantially homogenous" are used interchangeably to describe a protein or polypeptide which has been separated from components which naturally accompany it. A monom~ric protein is substantially pure when at least about 60 to 75~ of a sample exhibits a single polypeptide sequence. A substantially pure protein will typically comprise about 60 to 90~ W/W of a protein sample, more usually about 95~, and preferably will be over about 99~ pure. Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis or a protein sample, followed by visualizing a single polypeptide band upon st~;ning the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.
A protein is considered to be isolated when it is separated from the cont~m;n~nts which accompany it in its natural state. Thus, a polypeptide which is ~ WO94/20138 ~ CT~S94/02637 ~9 g chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components.
Protein purification The present invention provides polypeptides which are typically purified from cells transformed with recombinant nucleic acids encoding these proteins. Such protein purification can be accomplished by various methods well known in the art. A
protein having six contiguous histidine residues at its N-tPrm~nll~ can be purified by binding to ProBond resin (Invitrogen, San Diego, CA), as described in Example 2 below. Other useful methods of protein purification are well known in the art, and include those described, e.g., in Guide to Protein Purification, ed. M. Deutscher, vol.
182 of Methods in Enzymoloqy (ACA~Pm; c Press, Inc.: San Diego, 1990) and R. Scopes, Protein Purification:
Princi~les and Practice, Springer-Verlag: New York, 1982.
If necessary, the amino acid sequence of the proteins of the present invention can be det~rm~ned by protein sequencing methods well known in the art.
Protein modifications: fragments: fusion proteins The present invention also provides for polypeptides or fragments thereof which are substantially homologous to the primary structural sequence of the 66 kd protein. The present invention also embraces n vivo or n vitro chemical and biochemical modifications or which incorporating unusual amino acids. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labelling, e.g., with radionuclides, various enzymatic modifications, as will be readily appreciated by those well ~killed in the art. A variety of methods for labelling polypeptides and of substituents - 35 or labels useful for such purposes are well known in the 2~ PCT~S94/02637 ~
art and include radioactive isotopes such as 32p, ligands, which bind to labeled antiligands (e.g., antibodies), fluorophores, chemilllm~nescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods of labelling polypeptides are well known in the art. See, e.g., Molecular Cloning: A Laboratory ~m1~l, 2nd ed., Vol. 1-3, ed. Sambrook, et al., Cold Spring Harbor Laboratory Press (1989) or Current Protocols in Molecular Bioloqy, ed. F. Ausubel et ~1-, Greene Publishing and Wiley-Interscience: New York (1987 and periodic updates).
Besides substantially full-length polypeptides, the present invention provides for fragments of the polypeptides capable of eliciting EBV neutralizing antibodies. As used herein, the term fragment or segment, as applied to a polypeptide, will ordinarily be at least about 5 to 7 contiguous amino acids, typically at least about 9 to 13 contiguous amino acids, and most preferably at least about 20 to 30 or more contiguous amino acids.
For ;mm~lnological purposes, t~n~pm repeats of the polypeptides or polypeptide ~ragments of the present invention can be used as ;mm~lnogens, thereby producing more highly antigenic proteins.
The present invention also provides for fusion polypeptides comprising the 66 kd polypeptide or fragments thereof. Homologous polypeptides may be fusions between two or more sequences derived from the 66 kd protein or between the sequences of the 66 kd protein and a related protein. Likewise, heterologous ~usions may be constructed which would exhibit a combination of -WO 94/20L~8 ~ PCTIUS94/02637 ~ - 11-properties or activities of the derivative proteins.
See, e.g., Godowski et al. ~1988) Science 241:812-816.
Fusion proteins will typically be made by recombinant nucleic acid methods, but may be chemically 5 synthesized. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963) J. Amer.
Chem. Soc. 85:2149-2156.
Nucleic AcidS
The term present invention provides nucleic acids which encode a 66 kd polypeptide, fragment, homolog or variant, including, e.g., protein fusions or deletions. The nucleic acids of the present invention will possess a sequence which is either derived or substantially similar to a natural E~3V nucleic acid sequence encoding such a protein or one having substantial homology with this sequence or a portion thereof.
The nucleic acid compositions of this invention include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art.
Recombinant nucleic acids comprising sequences otherwise not naturally occurring are also provided by this invention. Although the wild type sequence may be employed, the wild type sequence will often be altered, e.g., by deletion, substitution, or insertion.
The nucleic acid sequences used in this invention will usually comprise at least about 5 codons (15 nucleotides), more usually at least about 7 to 15 codons, and most preferably at least about 35 codons.
One or more introns may also be present. This number of nucleotides is usually about the m;ntm~l length required WO94120138 2~ 19 PCT~S94/02637 for a successful probe that would hybridize specifically with a such a sequence.
Techniques for nucleic acid manipulation are described generally, for example, in Sambrook et al., ibid~, or Ausubel et al., ibid.. Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from such vendors as New England BioLabs, Boehringer ~Annheiml Amersham, Promega Biotec, U. S.
Biochemicals, New ~ngland Nuclear, and a number of other sources. The recombinant nucleic acid sequences used to produce fusion proteins of the present invention may be derived from natural or synthetic ~equences. Many natural gene sequences are obtA;n~hle from various cDNA
or from genomic libraries using appropriate probes. See, GPnR~nk, National Institutes of Health.
"Substantial homology" or "similaritY" A
nucleic acid or fragment thereof is "substantially homologous" (or "substantially simi~Arll) to another if, when optimally aligned (with appropriate nucleotide insertions or deletionc) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 60~ of the nucleotide bases, usually at least about 70~, more usually at least about 80~, preferably at least about 90~, and more preferably at least about 95 to 98~ of the nucleotide bases.
Alternatively, a nucleic acid or fragment (or its complementary strand) is substantially homologous (or s;m-lAr) with a 66 kd polypeptide-encoding nucleic acid when they are capable of hybridizing under selective hybridization conditions. Selectivity of hybridization exists when hybridization occurs which is substantially more selective than total lack of specificity.
Typically, selecti~e hybridization will occur when there is at least about 55~ homology over a stretch of at least Og4/20~8 ~ PCT~S94/~7 about 14 nucleotides, preferably at least about 65~, more preferably at least about 75~, and most preferably at least about 90~. See, ~n~h~ sa (1984) Nuc. Acids Res.
12:203-213. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will often be over a stretch of at least about 17 nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides.
Nucleic acid hybridization will be affected by such conditions as salt concentration (e.g., NaCl), temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30 C, typically in excess of 37, and preferably in excess of 45. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the com~bination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370.
"Isolated" or "subs~antially pure" or "purified. An "isolated" or "substantially pure~ or ~purified~ nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a m~ xeA polymer, which is substantially separated from other DNA sequences which naturally accompany a native hllm~n sequence, e.g., ribosomes, polymerases, and many other human genome sequences. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant WO94/20138 2~ PCT~S94/02637 *
or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems.
"Encodel' A nucleic acid is said to "encode" a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the polypeptide of a fragment thereof. The anti-sense strand of such a nucleic acid is also said to encode the sequence.
"O~erably linked" A nucleic acid sequence is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. Generally, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
~Recombinant~ The term "recombinant" nucleic acid is one which is not naturally occurring or is made by the artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.
Such is usually done to replace a codon with a r~71n~nt codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions.
Preparation of re~ombinant or chemically synthesized nucleic acids: ~ectors. transformation. host cells Large amounts of the nucleic acids of the present WOg4/20138 !~ ~ S6 ~1 9 PCT~S94/02637 invention may be produced by replication in a suitable host cell. The natural or synthetic DNA fragments coding for a desired fragment will be incorporated into recombinant nucleic acid constructs, typically DNA
constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the DNA
constructs will be suitable for autonomous replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to and integration within the genome of a cultured insect, m~mm~l ian, plant or other eukaryotic cell lines. The purification of nucleic acids produced by the methods of the present invention are describedj e.g., in Sambrook et al. (1989) or Ausubel et al. (1987 and periodic updates).
The nucleic acids of the present invention may also be produced by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862 or the triester method according to Matteucci et al. (1981) J.
Am. Chem. Soc~ lQ3:3185, and may be performed on commercial automated oligonucleotide synthesizers. A
double-stranded fragment may be obt~;ne~ from the single stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.
DNA constructs prepared for introduction into a prokaryotic or eukaryotic host will typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired polypeptide, and will preferably also include transcription and translational initiation regulatory se~uences operably linked to the polypeptide encoding segment. Expression vectors may include, for example, an origin of WO94120138 2 ~ ~ 6 7 i 9 PCT~S94/02637 ~
replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information ~ite~, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional term-n~tor sequences, and mRNA
stabilizing sequences. Secretion signals from polypeptides secreted from the host cell of choice may also be included where appropriate, thus allowing the protein to cross and/or lodge in cell membranes, and thus attain its functional topology or be secreted from the cell. Such vectors may be prepared by means of st~n~rd recombinant techniques well known in the art and discussed, for example, in Sambrook et al. (1989) or Ausubel et al. (1987).
The selection of an appropriate promoter and other necessary vector sequences will be selected so as to be functional in the host, and may, when appropriate, include those naturally associated with EBV genes.
Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al., 1989 or Ausubel et ~1., 1987); see also, e.g., Metzger et al.
1988), Nature 334:31-36. Many useful vectors are known in the art and may be obt~;ne~ such vendors as Stratagene, New England ~iolabs, Promega Biotech, and others. Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts. Useful yeast promoters include the promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible ~or maltose and galactose utilization, and others. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al. EP 73,657A. Appropriate nonnative m~mm~l ian promoters might include the early and f~
WO94/20138 ~'~5~ ~CT~S94/02637 late promoters from SV40 (Fiers et al. (1978) Nature 273:113) or promoters derived from murine molony leukemia virus, mouse ~mm~ry tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made. For appropriate enhancer and other expression control sequences see also Enhancers and Eukaryotic Gene Expression, Cold Spring Harbor Press, N.Y. (1983).
While such expression vectors may replicate autonomously, they may less preferably replicate by being inserted into the genome of the host cell, by methods well known in the art.
Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures the growth of only those host cells which express the inserts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.
The vectors cont~;n;ng the nucleic acids of interest can be transcribed in ~itro and the resulting RNA introduced into the host cell by well known methods (e.g., by injection. ~ee, T. Kubo et ~l., FE~S Lett.
241:119 (1988)), or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host, including electroporation; transfection employing calcium W094l20~8 21~ ~ 7 ~ ~ PCT~S94/02637 ~
chloride, rubidium chloride calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods. See generally, Sambrook et al. (1989) and Ausubel et al. (1987). The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.
~arge quantities of the nucleic acids and polypeptides of the present invention may be prepared by expressing the nucleic acids or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of Escherichia coli, although other prokaryotes, such as Bacillus subtilis or PseudomQnas may also be used.
~ mmA lian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect, ~mph;hian or avian species, may also be useful for production of the proteins of the present invention.
Propagation of m~mm~lian cells in culture is per se well known. See, Tissue Culture, Kruse and Patterson, ed., Academic Press (1973). Examples of cnmm~ly used m~mm~ lian host cell lines are VERO and XeLa cells, Ch~n~se hamster ovary (CHO) cells, and WI38, BHK, and COS
cell lines, although it will be appreciated by the skilled practitioner that other cell lines may be appropriate, e.g., to provide higher expression, desirable glycosylation patterns, or other features.
Clones are selected by using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule, prefera~ly the same DNA molecule. The transformant may be screened or, preferably, selected by any of the means well known Og4eOI38 ~ ~CT~S94/0~637 in the art, e.g., by resistance to such antibiotics as ampicillin, tetracycline.
Vaccines The present invention provides vaccines preparations comprising an imm-lnogenic amount of a polypeptide of the present invention. Each of these vaccines may comprise more than one of the proteins of the present invention, or a protein of the present invention in combination with another protein or other immunogen. By ~immllnogenic amount" is meant an amount capable of eliciting the production of antibodies directed against the polypeptide in an individual to which the vaccine has been ~mi n; ~tered.
Tmmllnogenic carriers may be used to enhance the immnnogenicity of the polypeptides of the present invention. Such carriers are soluble molecules, e.g., proteins and polysaccharides, or particles, e.g., liposomes and bacterial cells and membranes. Protein carriers may be joined to the 66 kd proteins of the present invention to form fusion proteins by recombinant means or by chemical coupling. Useful carriers and means of coupling such carriers to polypeptide antigens are well known in the art.
The vaccines of the present invention may be formulated by any of the means known to those skilled in the art. Such vaccines are typically prepared as injectables, either as liquid solutions or suspensions;
solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes.
The active immllnogenic ingredients are often mi XP~ with excipients or carriers which are ph~rm~ceutically acceptable and compatible with the W094/20~8 ~ 2i5 ~ PCT~S94102637 active ingredient. Suitable excipients are, e.g., water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. The concentration of the immunogenic polypeptide in injectable formulation~ will usually be in the range of 0.2 to 5 mg/ml.
In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include: alnminl~m hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglut~m;ne (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglut~mtne (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alan`ine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE),and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2~ s~ualene/Tween 80 emulsion. The effectiveness of an adjuvant may be det~rm;nPd by measuring the amount of antibodies directed against the ;mmllnogen resulting from ~m;n;ctration of the ;mmllnogen in vaccines which are also comprised of the various adjuvants.
The vaccines are conventionally ~m; n; stered parenterally by intravenous, subcutaneous, or intramuscular injection. Additional formulations and modes of ~m; n;stration may also be used, including suppositories and, in some cases oral formulations and liposomes, or others well known in the art. For suppositories, traditional binders and carriers may include, e.g., polyalkaline glycols or triglycerides.
Such suppositories may be formed from mixtures cont~;n;ng the analog in the range of 0.5~ by weight, preferably 1 ~5 to 2~. Oral formulations typically include such W094/20138 ~1S6~ PCT~S94/02637 excipients as p~ rm~ ceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10 to 95~ of the polypeptides of the present invention, preferably 25~ to 70~.
The polypeptides of the present invention may be formulated into the ~accine as neutral or salt forms.
Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) which are formed with inorganic acids, e.g., hydrochloric acid or phosphoric acids, or organic acids, e.g., acetic, oxalic, tartaric, or maleic acid. Salts ~ormed with the free carboxyl groups may also be derived from inorganic bases, e.g., sodium, potassium, ~mmnn;um, calcium, or ferric hydroxides, and organic bases, e.g., isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, and procaine.
The vaccines are ~m; n; stered in a m~nnPr compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be ~Am; n; ~tered, which i9 generally in the range of 5 to 250 mic oyldms of protein per dose, depends on the subject to be treated, capacity of the individual's ; mm~n~ system to synthesize antibodies, and the degree of protection desired.
Preciqe amounts of active ingredient required to be ~m; n; ~tered may depend on the judgment o~ the physician and may be peculiar to each individual, but such a determ;n~tion is within the skill of such a physician.
The vaccine may be given in a single dose or multiple dose schedule. A multiple dose s~heAl~le i9 one in which a primary course of vaccination may include 1 to 10 separate doses, followed by other doses ~Am; n; stered WO94/20138 215 6 719 PCT~S94/02~7 ~
at subsequent time intervals as required to maintain and or reinforce the imm~ne response, e.g., at 1 to 4 months for a second dose, and if needed, a subsequent dose(s) after several months.
The invention will be better understood by reference to the following examples, which are intended to merely illustrate the best mode now known for practicing the invention. The invention is not to be considered limited thereto, however.
Examples Example l: Identification of E~itope for EBV-Neutralizinq Antibody To identify the epitope for EBV-neutralizing antibody, the following recombinant plasmids were constructed. A 4.3 XhoII-~Ç~II DNA fragment cont~;n;ng the entire EBV gp350/220 coding ~nm~in (except the signal peptide) was subcloned from the pl~qm;~ pMA102 into the baculovirus expression vector pBlueBacHisC (Invitrogen), resulting in plasmid pBac-TTI350. This fragment contains the entire region of gp350/220 which i5 the protein present on the outer surface of EBV-infected cells. An NcoI fragment encoding the serine and threonine-rich sequences was deleted from pBac-TTI350 to generate plasmid pBac-TTI300. The NcoI fragment was recloned at the NcoI site of plasmid pBlue~ac~isC to generate pBac-TTI250. These manipulations employed E. coli strain Top 10 (Invitrogen). A synthetic DNA coding for the nine amino acids Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu was also introduced upstream of the se~uence coding for 66 kd protein. This peptide has been shown to be involved in me~i~ting EBV attachment to human B-cell receptor CR2.
Construction of such a protein will not only produce WO94/20138 ~ S67~ PCT~S94102637 neutralizing antibody but will also inhibit viral binding and entry into the B-cells.
A baculovirus transfer vector is used to replace the viral polyhedrin gene with the gene o~
interest by homologous recombination. Sequences which flank the polyhedrin gene in the wild-type genome are positioned 5' to 3' to the expression cassette on the transfer vector. Following cotransfection, homologous recombination between these sequences results in a recombinant ~irus with the gene of interest expressed under the control of the viral polyhedrin enhancer/promoter elements. The vector pBlueBacHisC used here also expresses galactosidase to provide a blue reporter for visual identification of blue recombinant plaques. The recombinant virus was produced and purified according to the method described in the Invitrogen m;3 n~
The expression of the gp350/220 sequence in insect cells derived from Spodoptera frugiperda ovarian cells (Sf9 Cells, Invitrogen) was confirmed by Western blot analysis in the following m~nn~r, Insect cells were infected with virus cont~ n ~ ng recombinant plasmid pBac-TTI350, pBac-TTI300 and pBac-TTI250, respectively. After three days, a lml sample of cells was L~mo~ed from each culture. As positive controls for molecular weights of 350 and 220 kd, l ml samples of Raji cells infected with EBV were also u~ed in the following test. The cells were pelleted and dissolved in lO0 ~l of T.~Qmm1 i buffer.
After boiling for 2 min, the samples were loaded on a lO~
SDS-polyacrylamide gel and electrophore~ed overnight at 70 volts. The proteins were transferred electrophoretically to a nitrocellulose membrane.
Nonspecific binding of the protein was blocked by treating the membrane with 5~ nonfat dry milk in TBST (lO
mM Tris, pH 8.0/l mM EDTA/0.05~ Tween-20). High-titer , WO94/20138 ~1 ~ 6 ~19 PCT~S94/02~7 EBV-;mm~ln~ human serum and a monoclonal EBV-neutralizing antibody to gp350/220 (DuPont, Boston, MA), respectively, were added to the blots and incubated for 1 hr, washed 3 times for 5 min each with TBST, and then incubated with anti-human IgG-alkaline phosphatase conjugate for 30 min.
After washing 3 times with TBST, the color was developed.
Cells infected with recombinant virus pBac-TTI350 showed two bands with molecular weights of 350 and 220 kd, with both EBV ;mmllne human serum and monoclonal EBV neutralizing antibody. The recombinant protein bands appeared in the same position as the protein bands from the Raji cells infected with EBV. No reaction was seen with cells infected with recombinant virus pBac-TTI300, from which the serine- and threonine-rich sequence of gp350/220 had been deleted. Because the TTI300 plasmid did not react, the serine- and threonine-rich sequence appears to be the likely epitope for neutralizing antibody. This result was further confirmed by ;mmllnoreaction of human serum and monoclonal antibody to cells infected with recombinant virus pBac-TTI250 which contains the serine- and threonine-rich sequences which has been deleted from pBac-TTI300. The size of the reactive protein from pBAC-TTI250 was 66 kd.
Example 2: Purification of Recombinant Proteins The vector pBl--~R~;8C contains the DNA
sequence below the translation start codon which produces a six-histidine peptide at the N-tPrm;n~l region of the expressed protein. This peptide has an affinity for the ProBond resin (Invitrogen) and thus allows one-step purification. For each of the two proteins, about 500 ml of insect cells Sf9 was grown at a density of 2 x 106 cells/ml in a 500 ml spinner ~lask. Cells were infected with high-titer viral stock of either the pBac-TTI250-infected virus (66 kd protein) or the pBac-TTI350-W094/20138 ~ S671~ PCT/US94/02637 infected virus (the 350/220 kd protein). Then the cells were grown for 3 days. The cells were pelleted by centrifugation and suspended in 20 mM sodium phosphate and 500 mM NaCl and lysed by sonication and centrifuged to remove cell debris. The recom~inant proteins were puri~ied from the supernatant through ProBond resin by the method described by Invitrogen. First, the 6-histidine end of the recombinant protein binds to the ProBond resin. Then the reco-mbinant protein is cleaved off by enterokinase applied to the column. This isolation method gave single protein bands (66 kd or 350/220 kd proteins) on SDS-polyacrylamide gel. The 350 and 220 kd bands were in the same position for recombinant and Raji-cell-derived proteins. About 5 mg of purified protein was obtained from each 500 ml of culture.
Because the 66 kd recombinant protein derived from gp350/220 is ;mml~noreactive with both the EBV lmml~n~
human serum and monoclonal antibody that neutralizes EBV
virus, this protein can be used to develop vaccine for EBV. In addition, because the 66 kd protein also has a nine-amino acid sequence for EBV attachment to B-cells, vaccines developed with this protein also should inhibit viral binding and entry into B-cells.
Expression in baculovirus provides several advantayes. While E. coli synthesize unglycosylated proteins, and yeast produce proteins which are differently glycosylated, proteins produced in baculovirus are glycosylated and have a glycosylation pattern similar to that resulting from expression in mAmm~lian cells. A further advantage i9 that much larger quantities of pure protein can be obtained from baculovirus than from mAmm~lian cells. Moreover, the expression of recombinant gp350/220 in m~mm~l ian cells is generally very unstable. Therefore, either the 66 kd or WO94/20138 21~ 6 ~ ~ 9 PCT~S94/02637 ~
the 350/220 kd protein produced in insect cells provides a more stable and efficient method of making purified vaccine protein.
Smaller proteins provide several advantages over large proteins for vaccine development. Smaller proteins permit the injection of more moles of epitope per weight or injection volume of vaccine. Smaller proteins may be processed more efficiently recombinantly and ;mmnnologically. Smaller proteins are less vulnerable to protease attack because they are less likely to have amino acid combinations for which the proteases are specific. Smaller proteins have fewer epitopes and elicit a more concentrated response.
Each of the publications and patents cited above are incorporated by reference.
While the invention has been described in connection with certain embo~;m~nts thereof, various modifications which may be apparent to one of skill in the art also fall within the scope of the invention as defined by the appended claims. The scope of the invention, therefore, should be det~rm; n~ not with reference to the above description, but should instead be det~rm;ne~ with reference to the appended claims, along with the full scope of e~uivalents to which such claims are entitled.
AND ITS USE IN VACCINE
DESCRIPTION
TECHNICAL FIELD
The present invention relates generally to the production of vaccines, specifically to vaccines effective against Epstein-Barr virus (EBV) infection based on the gp350/220 of EBV and on a 66 kd serine- and threonine-rich portion of gp350/220 of EBV.
BACKGROUND ART
Epstein-Barr virus (EBV) is a member of the herpesvirus family which infects most hllm~nc The manifestations of primary infection in normal hllm~nc range from insignificant illness to infectious mononucleosis (Roberts, G.B., Diaqnosis and Clinical Testinq 27, 16-21, 1989). Persistent or latent EBV
infection is an important etiologic factor in Burkitt's lymphoma and nasopharyngeal carcinoma. EBV is an opportunistic pathogen often developing in immnnosuppressed patients who have allografts or in patients with acquired ;mmnne deficiency syndrome (AIDS).
EBV has also been implicated in rheumatoid arthritis and chronic fatigue syndrome. Because of the associated morbidity and mortality, prevention of EBV infection is desirable.
Because EBV does not replicate well in vitro, a systematic approach to selection and production of avirulent virus for preventive ;mmlln;zation is not WO94/20138 Z~S6~ ~ PCT~S94/02637 ~
feasible. Since EBV causes lymphocyte proliferation and is a presumed etiological agent of human malignancies, it is very important that virus preparations used for ;mml~nization be free of potential transforming genes.
For this reason, effective vaccines based on isolated proteins presented on the outer surface of the EBV virus and/or of EBV-infected cells are desirable.
Recombinant proteins provide several advantages over those purified from m~mm~lian tissues infected with the virus. For example, they can be readily produced in large quantities and at high purity. Especially valuable would be vaccines capable not only of neutralizing EBV
virus post-infection, but also to prevent viral binding and entry into B-cells.
Brief Description of the Background Art The principal components of the outer surface of EBV are glycoproteins of 350, 220 and 85 kilodaltons (Pearson, G.R. and Luka, J. In: M.A. Epstein and B.G.
Achong (Eds), The Epstein-Barr Virus. Recent Advances, pp. 48-73. William He;n~m~nn Medical Books, London.) These glycoproteins are also present on the outer surface of infected cell in which the virus is replicating.
Polyclonal and monoclonal antibodies directed against these proteins react with the surface of productively infected cells and neutralize the virus (ibid.).
However, target membrane antigens for antibody-dependent cellular cytotoxicity (ADCC) appeared to be associated with gp350 and gp220 but not with gp85 (ibid.). The EBV
gp350/220 has also been identified as the ligand that m~ tes attachment of the virus to receptor CR2 of human B lymphocytes (Nemerow, G.R., et al., J. Virol. 61, 1416-1420, 1987). The sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu, which corresponds to the N-t~rm;nllc region of gp350/220, has been found to be the epitope responsible W094/20138 ~ 71 9 PCT~S94/OZ~7 for attachment (Nemerow, G.R., et al., Cell 56, 369-377, 1989).
The gp350 and gp220 proteins are encoded by 3.2 and 2.5 kb RNAs which map to the same DNA fragment (~eisel, C., et al., J. Virol. 54, 665-674, 1985).
Antisera raised in rabbits against the gp350/220 protein expressed in E. coli specifically 1mml~noprecipitate gp350 and gp220, react with the plasma membrane of infected cells, and neutralize virus, particularly after the addition of complement. However, multiple injections of substantial quantities of protein are necessary to elicit an effective response. The poor 1mm~nogenicity of gp350/220 expressed in E. coli may be attributable to the absence of glycosylation and proper folding. When expressed in m~mm~lian cells, gp350/220 is highly immunogenic and elicits virus-neutralizing antibodies (Whang, Y., et al., J. Virol. 61, 1796-1807, 1987), indicating that glycosylation plays an important role in the immunogenicity of the glycoprotein. However, the expression of recombinant gp350/220 in m~mm~lian cells is generally very unstable.
Several features of the proteins have been predicted from the DNA and mRNA nucleotide sequence (Beisel, C., et al., J. Virol. 54, 665). The primary translation product of gp350 is a 907 amino acid polypeptide, while that of gp220 is a 710 amino acid polypeptide. At the amino t~rm;nllc of both proteins is an 18-amino acid region which is likely to be a cleavable signal peptide. A single hydrophobic domain which likely functions as a tr~nsm~mhrane anchor is located 26 amino acids from the carboxy terminus of both proteins. The 850 amino acids of gp350 and the 652 amino acids of gp220 between the putative signal and anchor sequences are serine- and threonine-rich and contain 35 (gp350) or 24 (gp220) asparagine-X-serine or -C-threonine sequences, WO94120138 21~ PCT~S94/02637 respectively, which serve as potential signals for N-linked glycosylation. These regions are therefore likely to be present on the outer surface of the membrane.
BRIEF SUMMARY OF THE lN V~N'l'lON
The present invention provides recombinant polypeptides based on the 66 kd serine- and threonine-rich portion of gp350/220 and fragments thereof which are useful as vaccines capable of eliciting EBV-neutralizing antibodies in m~mm~l ian subjects. Preferably, these polypeptides further incorporate a sequence encoding a nine amino acid peptide sequence, Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu, which is involved in mediating EBV
attachment to human B-cells. Vaccines based on polypeptides comprising both the 66 kd polypeptide and this nonamer peptide are also capable of inhibiting viral binding and entry into B-cells.
Accordingly, one aspect of the present invention is a substantially pure polypeptide consisting essentially of the 66 kd serine- and threonine- rich portion of gp350/220 of the Epstein-Barr virus or fragments thereof capable of eliciting EBV-neutralizing antibodies in a m~mm~ 1, Another aspect of the present invention is a substantially pure polypeptide comprising the 66 kd serine- and threonine- rich portion of gp350/220 of the Epstein-Barr virus or fragments thereof and the peptide sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu capable of eliciting EBV-neutralizing antibodieg in a m~mm~l, Such polypeptides are preferentially glycosylated.
Also embraced by the present invention are nucleic sequence encoding these polypeptides and expression vectors comprising such nucleic acids and WO94/20138 21 ~6 ~ PCT~S94/02637 expression control sequences that are operably linked to the nucleic acid and effective in directing expression of said nucleic acid in a cell. A further aspect of the invention is a cell containing such an expression vector as well as methods of producing the polypeptides of the present invention comprising growing such a cell under conditions that permit the production of the polypeptide.
Another aspect of the invention is a vaccine composition comprising an ;mmllnogenic amount of a polypeptide of the present invention admixed with a pharmaceutically acceptable carrier. The inventlon further embraces a method of protecting a m~mm~ 1 from EBV
infection comprising ~mintstering to said m~m~l an immunologically effective dose of such a vaccine composition.
Still another aspect of the invention is a method of producing a su~stantially pure EBV gp350/220 protein, said method comprising subcloning the complete EBV gp350/220 gene into the baculovirus expression vector pBlueBacHisC to form a plasmid pBac-TTI350 which comprises the EBV gp350/220 gene and a 6-histidine peptide gene. This plasmid is used to replace a viral gene encoding the EBV gp350/220 protein and the 6-histidine polypeptide. Then insect cells are transfected with the virus comprising these genes. ~ater the transfected insect cells are harvested and the recombinant EBV gp350/220 protein is ~eparated from the transfected insect cells. Then the EBV gp350/220 protein is puri~ied on a column whose resin has an affinity for a 6-histidine peptide. Another aspect of the present invention is the protein produced by this method.
DETAILED DESCRIPTION QF THE lNv~NllON
The present invention provides recombinant 35 polypcptides based on the EBV gp350/220 protein and on WO94/20138 21~ ~ ~ 19 PCT~S94/02637 ~
the 66 kd serine- and threonine-rich portion o~ gp350/220 which are 1mmllnoreactive with both the EBV imml~ne human serum and a monoclonal antibody that neutralizes EBV
virus. Also provided are polypeptides which further incorporate a sequence encoding a peptide sequence involved in mediating EBV attachment to human B-cells.
Vaccines based on such polypeptides are capable not only of eliciting the production of neutralizing antibodie~
against EBV but also of inhibiting viral binding and entry into B-cells.
Polype~tides The term "gp350/220" refers to the 350 kd and 220 kd outer membrane glycoproteins of Epstein-Barr virus (EBV) which are also present on the ouser surface of infected cells in which EBV is replica~ing. The term also embraces variants or fragments of gp350/220.
The term "66 kd protein" refers to the serine-and threonine- rich portion of gp350/220, encoded by the NcoI fragment of the DNA fragment cont~; n ing the complete EBV gp350/220 coding ~om~;n represented by base pairs numbered 1361-2292 from the initiation codon of the EBV
gp350/220 DNA coding ~om~ln. (Beisel, C., et al., J.
Virol. 54, 665) The term also embraces variants or fragments of the 66 kd protein. Preferably such polypeptides also comprise a peptide sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu, which is involved in mediating EBV attachment to human B-cell receptor CR2.
This nine-amino acid sequence is generally introduced at the amino- or carboxy-tprm;nl~s of the 66 kd protein, most preferably at the amino-t~rm;n-lc.
For the sake of convenience, the term "66 kd protein" as used herein al~o refers to polypeptides comprising the 66 kd polypeptide and this nine amino acid peptide. Only such polypeptides as are capable o~
-WO 94/20L~8 ,~ f~ 71~ PCTIUS94/02637 eliciting EBV-neutralizing antibodies in a human subject are considered to be within the scope of the present invention.
An "-mml~nologically effective dose" of such a 5 polypeptide is an amount capable of eliciting EBV-neutralizing antibodies in a human subject.
Ordinarily, the proteins of the present invention will be at least about 50~ homologous to the 66 kd protein sequence, preferably in excess of about 90~, 10 and, more preferably, at least about 95~ homologous.
Also included are proteins encoded by DNA which hybridize under high or low stringency conditions, to nucleic acids encoding the 66 kd protein, as well as closely related polypeptides or proteins retrieved by antisera to the 66 15 kd protein.
The length of polypeptide sequences compared for homology will generally be at least about 16 amino acids, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 20 residues, and preferably more than about 35 residues.
~ ubstantial homoloqy or identity The tenn ~Isubstantial homology~ or llsubstantial identity", when referring to polypeptides, indicates that the polypeptide or protein in question exhibits at least about 30~
25 identity with an entire naturally occurring protein or a portion thereof, usually at least about 70~ identity, and preferably at least about 95~ identity.
Homology, for polypeptides, is typically measured using sequence analysis software. See, e.g., 30 Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wisconsin 53705.
Protein analysis software matches similar sequences using measure of homology assigned to various substitutions, 35 deletions, substitutions, and other modifications.
W094/20138 2 ~S~ PCT~S94/02637 Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glut~m'n~; serine, threonine;
lysine, arginine; and phenylalanine, tyrosine.
A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9 to 13 amino acids, and, in various embodiments, at least about 17 or more amino acids.
The polypeptides of the present invention are generally soluble, but the polypeptide also can be coupled to a solid phase support. Many such supports are well known in the art.
"Isolated" The terms "isolated,"
"substantially pure," and "substantially homogenous" are used interchangeably to describe a protein or polypeptide which has been separated from components which naturally accompany it. A monom~ric protein is substantially pure when at least about 60 to 75~ of a sample exhibits a single polypeptide sequence. A substantially pure protein will typically comprise about 60 to 90~ W/W of a protein sample, more usually about 95~, and preferably will be over about 99~ pure. Protein purity or homogeneity may be indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis or a protein sample, followed by visualizing a single polypeptide band upon st~;ning the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.
A protein is considered to be isolated when it is separated from the cont~m;n~nts which accompany it in its natural state. Thus, a polypeptide which is ~ WO94/20138 ~ CT~S94/02637 ~9 g chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be substantially free from its naturally associated components.
Protein purification The present invention provides polypeptides which are typically purified from cells transformed with recombinant nucleic acids encoding these proteins. Such protein purification can be accomplished by various methods well known in the art. A
protein having six contiguous histidine residues at its N-tPrm~nll~ can be purified by binding to ProBond resin (Invitrogen, San Diego, CA), as described in Example 2 below. Other useful methods of protein purification are well known in the art, and include those described, e.g., in Guide to Protein Purification, ed. M. Deutscher, vol.
182 of Methods in Enzymoloqy (ACA~Pm; c Press, Inc.: San Diego, 1990) and R. Scopes, Protein Purification:
Princi~les and Practice, Springer-Verlag: New York, 1982.
If necessary, the amino acid sequence of the proteins of the present invention can be det~rm~ned by protein sequencing methods well known in the art.
Protein modifications: fragments: fusion proteins The present invention also provides for polypeptides or fragments thereof which are substantially homologous to the primary structural sequence of the 66 kd protein. The present invention also embraces n vivo or n vitro chemical and biochemical modifications or which incorporating unusual amino acids. Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labelling, e.g., with radionuclides, various enzymatic modifications, as will be readily appreciated by those well ~killed in the art. A variety of methods for labelling polypeptides and of substituents - 35 or labels useful for such purposes are well known in the 2~ PCT~S94/02637 ~
art and include radioactive isotopes such as 32p, ligands, which bind to labeled antiligands (e.g., antibodies), fluorophores, chemilllm~nescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods of labelling polypeptides are well known in the art. See, e.g., Molecular Cloning: A Laboratory ~m1~l, 2nd ed., Vol. 1-3, ed. Sambrook, et al., Cold Spring Harbor Laboratory Press (1989) or Current Protocols in Molecular Bioloqy, ed. F. Ausubel et ~1-, Greene Publishing and Wiley-Interscience: New York (1987 and periodic updates).
Besides substantially full-length polypeptides, the present invention provides for fragments of the polypeptides capable of eliciting EBV neutralizing antibodies. As used herein, the term fragment or segment, as applied to a polypeptide, will ordinarily be at least about 5 to 7 contiguous amino acids, typically at least about 9 to 13 contiguous amino acids, and most preferably at least about 20 to 30 or more contiguous amino acids.
For ;mm~lnological purposes, t~n~pm repeats of the polypeptides or polypeptide ~ragments of the present invention can be used as ;mm~lnogens, thereby producing more highly antigenic proteins.
The present invention also provides for fusion polypeptides comprising the 66 kd polypeptide or fragments thereof. Homologous polypeptides may be fusions between two or more sequences derived from the 66 kd protein or between the sequences of the 66 kd protein and a related protein. Likewise, heterologous ~usions may be constructed which would exhibit a combination of -WO 94/20L~8 ~ PCTIUS94/02637 ~ - 11-properties or activities of the derivative proteins.
See, e.g., Godowski et al. ~1988) Science 241:812-816.
Fusion proteins will typically be made by recombinant nucleic acid methods, but may be chemically 5 synthesized. Techniques for synthesis of polypeptides are described, for example, in Merrifield (1963) J. Amer.
Chem. Soc. 85:2149-2156.
Nucleic AcidS
The term present invention provides nucleic acids which encode a 66 kd polypeptide, fragment, homolog or variant, including, e.g., protein fusions or deletions. The nucleic acids of the present invention will possess a sequence which is either derived or substantially similar to a natural E~3V nucleic acid sequence encoding such a protein or one having substantial homology with this sequence or a portion thereof.
The nucleic acid compositions of this invention include RNA, cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified or contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art.
Recombinant nucleic acids comprising sequences otherwise not naturally occurring are also provided by this invention. Although the wild type sequence may be employed, the wild type sequence will often be altered, e.g., by deletion, substitution, or insertion.
The nucleic acid sequences used in this invention will usually comprise at least about 5 codons (15 nucleotides), more usually at least about 7 to 15 codons, and most preferably at least about 35 codons.
One or more introns may also be present. This number of nucleotides is usually about the m;ntm~l length required WO94120138 2~ 19 PCT~S94/02637 for a successful probe that would hybridize specifically with a such a sequence.
Techniques for nucleic acid manipulation are described generally, for example, in Sambrook et al., ibid~, or Ausubel et al., ibid.. Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from such vendors as New England BioLabs, Boehringer ~Annheiml Amersham, Promega Biotec, U. S.
Biochemicals, New ~ngland Nuclear, and a number of other sources. The recombinant nucleic acid sequences used to produce fusion proteins of the present invention may be derived from natural or synthetic ~equences. Many natural gene sequences are obtA;n~hle from various cDNA
or from genomic libraries using appropriate probes. See, GPnR~nk, National Institutes of Health.
"Substantial homology" or "similaritY" A
nucleic acid or fragment thereof is "substantially homologous" (or "substantially simi~Arll) to another if, when optimally aligned (with appropriate nucleotide insertions or deletionc) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 60~ of the nucleotide bases, usually at least about 70~, more usually at least about 80~, preferably at least about 90~, and more preferably at least about 95 to 98~ of the nucleotide bases.
Alternatively, a nucleic acid or fragment (or its complementary strand) is substantially homologous (or s;m-lAr) with a 66 kd polypeptide-encoding nucleic acid when they are capable of hybridizing under selective hybridization conditions. Selectivity of hybridization exists when hybridization occurs which is substantially more selective than total lack of specificity.
Typically, selecti~e hybridization will occur when there is at least about 55~ homology over a stretch of at least Og4/20~8 ~ PCT~S94/~7 about 14 nucleotides, preferably at least about 65~, more preferably at least about 75~, and most preferably at least about 90~. See, ~n~h~ sa (1984) Nuc. Acids Res.
12:203-213. The length of homology comparison, as described, may be over longer stretches, and in certain embodiments will often be over a stretch of at least about 17 nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides.
Nucleic acid hybridization will be affected by such conditions as salt concentration (e.g., NaCl), temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30 C, typically in excess of 37, and preferably in excess of 45. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the com~bination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370.
"Isolated" or "subs~antially pure" or "purified. An "isolated" or "substantially pure~ or ~purified~ nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a m~ xeA polymer, which is substantially separated from other DNA sequences which naturally accompany a native hllm~n sequence, e.g., ribosomes, polymerases, and many other human genome sequences. The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant WO94/20138 2~ PCT~S94/02637 *
or cloned DNA isolates and chemically synthesized analogues or analogues biologically synthesized by heterologous systems.
"Encodel' A nucleic acid is said to "encode" a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the polypeptide of a fragment thereof. The anti-sense strand of such a nucleic acid is also said to encode the sequence.
"O~erably linked" A nucleic acid sequence is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. Generally, operably linked means that the DNA sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
~Recombinant~ The term "recombinant" nucleic acid is one which is not naturally occurring or is made by the artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.
Such is usually done to replace a codon with a r~71n~nt codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions.
Preparation of re~ombinant or chemically synthesized nucleic acids: ~ectors. transformation. host cells Large amounts of the nucleic acids of the present WOg4/20138 !~ ~ S6 ~1 9 PCT~S94/02637 invention may be produced by replication in a suitable host cell. The natural or synthetic DNA fragments coding for a desired fragment will be incorporated into recombinant nucleic acid constructs, typically DNA
constructs, capable of introduction into and replication in a prokaryotic or eukaryotic cell. Usually the DNA
constructs will be suitable for autonomous replication in a unicellular host, such as yeast or bacteria, but may also be intended for introduction to and integration within the genome of a cultured insect, m~mm~l ian, plant or other eukaryotic cell lines. The purification of nucleic acids produced by the methods of the present invention are describedj e.g., in Sambrook et al. (1989) or Ausubel et al. (1987 and periodic updates).
The nucleic acids of the present invention may also be produced by chemical synthesis, e.g., by the phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862 or the triester method according to Matteucci et al. (1981) J.
Am. Chem. Soc~ lQ3:3185, and may be performed on commercial automated oligonucleotide synthesizers. A
double-stranded fragment may be obt~;ne~ from the single stranded product of chemical synthesis either by synthesizing the complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.
DNA constructs prepared for introduction into a prokaryotic or eukaryotic host will typically comprise a replication system recognized by the host, including the intended DNA fragment encoding the desired polypeptide, and will preferably also include transcription and translational initiation regulatory se~uences operably linked to the polypeptide encoding segment. Expression vectors may include, for example, an origin of WO94120138 2 ~ ~ 6 7 i 9 PCT~S94/02637 ~
replication or autonomously replicating sequence (ARS) and expression control sequences, a promoter, an enhancer and necessary processing information ~ite~, such as ribosome-binding sites, RNA splice sites, polyadenylation sites, transcriptional term-n~tor sequences, and mRNA
stabilizing sequences. Secretion signals from polypeptides secreted from the host cell of choice may also be included where appropriate, thus allowing the protein to cross and/or lodge in cell membranes, and thus attain its functional topology or be secreted from the cell. Such vectors may be prepared by means of st~n~rd recombinant techniques well known in the art and discussed, for example, in Sambrook et al. (1989) or Ausubel et al. (1987).
The selection of an appropriate promoter and other necessary vector sequences will be selected so as to be functional in the host, and may, when appropriate, include those naturally associated with EBV genes.
Examples of workable combinations of cell lines and expression vectors are described in Sambrook et al., 1989 or Ausubel et ~1., 1987); see also, e.g., Metzger et al.
1988), Nature 334:31-36. Many useful vectors are known in the art and may be obt~;ne~ such vendors as Stratagene, New England ~iolabs, Promega Biotech, and others. Promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters may be used in prokaryotic hosts. Useful yeast promoters include the promoter regions for metallothionein, 3-phosphoglycerate kinase or other glycolytic enzymes such as enolase or glyceraldehyde-3-phosphate dehydrogenase, enzymes responsible ~or maltose and galactose utilization, and others. Suitable vectors and promoters for use in yeast expression are further described in Hitzeman et al. EP 73,657A. Appropriate nonnative m~mm~l ian promoters might include the early and f~
WO94/20138 ~'~5~ ~CT~S94/02637 late promoters from SV40 (Fiers et al. (1978) Nature 273:113) or promoters derived from murine molony leukemia virus, mouse ~mm~ry tumor virus, avian sarcoma viruses, adenovirus II, bovine papilloma virus or polyoma. In addition, the construct may be joined to an amplifiable gene (e.g., DHFR) so that multiple copies of the gene may be made. For appropriate enhancer and other expression control sequences see also Enhancers and Eukaryotic Gene Expression, Cold Spring Harbor Press, N.Y. (1983).
While such expression vectors may replicate autonomously, they may less preferably replicate by being inserted into the genome of the host cell, by methods well known in the art.
Expression and cloning vectors will likely contain a selectable marker, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures the growth of only those host cells which express the inserts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxic substances, e.g. ampicillin, neomycin, methotrexate, etc.; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for Bacilli. The choice of the proper selectable marker will depend on the host cell, and appropriate markers for different hosts are well known in the art.
The vectors cont~;n;ng the nucleic acids of interest can be transcribed in ~itro and the resulting RNA introduced into the host cell by well known methods (e.g., by injection. ~ee, T. Kubo et ~l., FE~S Lett.
241:119 (1988)), or the vectors can be introduced directly into host cells by methods well known in the art, which vary depending on the type of cellular host, including electroporation; transfection employing calcium W094l20~8 21~ ~ 7 ~ ~ PCT~S94/02637 ~
chloride, rubidium chloride calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; infection (where the vector is an infectious agent, such as a retroviral genome); and other methods. See generally, Sambrook et al. (1989) and Ausubel et al. (1987). The cells into which have been introduced nucleic acids described above are meant to also include the progeny of such cells.
~arge quantities of the nucleic acids and polypeptides of the present invention may be prepared by expressing the nucleic acids or portions thereof in vectors or other expression vehicles in compatible prokaryotic or eukaryotic host cells. The most commonly used prokaryotic hosts are strains of Escherichia coli, although other prokaryotes, such as Bacillus subtilis or PseudomQnas may also be used.
~ mmA lian or other eukaryotic host cells, such as those of yeast, filamentous fungi, plant, insect, ~mph;hian or avian species, may also be useful for production of the proteins of the present invention.
Propagation of m~mm~lian cells in culture is per se well known. See, Tissue Culture, Kruse and Patterson, ed., Academic Press (1973). Examples of cnmm~ly used m~mm~ lian host cell lines are VERO and XeLa cells, Ch~n~se hamster ovary (CHO) cells, and WI38, BHK, and COS
cell lines, although it will be appreciated by the skilled practitioner that other cell lines may be appropriate, e.g., to provide higher expression, desirable glycosylation patterns, or other features.
Clones are selected by using markers depending on the mode of the vector construction. The marker may be on the same or a different DNA molecule, prefera~ly the same DNA molecule. The transformant may be screened or, preferably, selected by any of the means well known Og4eOI38 ~ ~CT~S94/0~637 in the art, e.g., by resistance to such antibiotics as ampicillin, tetracycline.
Vaccines The present invention provides vaccines preparations comprising an imm-lnogenic amount of a polypeptide of the present invention. Each of these vaccines may comprise more than one of the proteins of the present invention, or a protein of the present invention in combination with another protein or other immunogen. By ~immllnogenic amount" is meant an amount capable of eliciting the production of antibodies directed against the polypeptide in an individual to which the vaccine has been ~mi n; ~tered.
Tmmllnogenic carriers may be used to enhance the immnnogenicity of the polypeptides of the present invention. Such carriers are soluble molecules, e.g., proteins and polysaccharides, or particles, e.g., liposomes and bacterial cells and membranes. Protein carriers may be joined to the 66 kd proteins of the present invention to form fusion proteins by recombinant means or by chemical coupling. Useful carriers and means of coupling such carriers to polypeptide antigens are well known in the art.
The vaccines of the present invention may be formulated by any of the means known to those skilled in the art. Such vaccines are typically prepared as injectables, either as liquid solutions or suspensions;
solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes.
The active immllnogenic ingredients are often mi XP~ with excipients or carriers which are ph~rm~ceutically acceptable and compatible with the W094/20~8 ~ 2i5 ~ PCT~S94102637 active ingredient. Suitable excipients are, e.g., water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. The concentration of the immunogenic polypeptide in injectable formulation~ will usually be in the range of 0.2 to 5 mg/ml.
In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include: alnminl~m hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglut~m;ne (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglut~mtne (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alan`ine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE),and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2~ s~ualene/Tween 80 emulsion. The effectiveness of an adjuvant may be det~rm;nPd by measuring the amount of antibodies directed against the ;mmllnogen resulting from ~m;n;ctration of the ;mmllnogen in vaccines which are also comprised of the various adjuvants.
The vaccines are conventionally ~m; n; stered parenterally by intravenous, subcutaneous, or intramuscular injection. Additional formulations and modes of ~m; n;stration may also be used, including suppositories and, in some cases oral formulations and liposomes, or others well known in the art. For suppositories, traditional binders and carriers may include, e.g., polyalkaline glycols or triglycerides.
Such suppositories may be formed from mixtures cont~;n;ng the analog in the range of 0.5~ by weight, preferably 1 ~5 to 2~. Oral formulations typically include such W094/20138 ~1S6~ PCT~S94/02637 excipients as p~ rm~ ceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, and magnesium carbonate. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10 to 95~ of the polypeptides of the present invention, preferably 25~ to 70~.
The polypeptides of the present invention may be formulated into the ~accine as neutral or salt forms.
Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) which are formed with inorganic acids, e.g., hydrochloric acid or phosphoric acids, or organic acids, e.g., acetic, oxalic, tartaric, or maleic acid. Salts ~ormed with the free carboxyl groups may also be derived from inorganic bases, e.g., sodium, potassium, ~mmnn;um, calcium, or ferric hydroxides, and organic bases, e.g., isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, and procaine.
The vaccines are ~m; n; stered in a m~nnPr compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be ~Am; n; ~tered, which i9 generally in the range of 5 to 250 mic oyldms of protein per dose, depends on the subject to be treated, capacity of the individual's ; mm~n~ system to synthesize antibodies, and the degree of protection desired.
Preciqe amounts of active ingredient required to be ~m; n; ~tered may depend on the judgment o~ the physician and may be peculiar to each individual, but such a determ;n~tion is within the skill of such a physician.
The vaccine may be given in a single dose or multiple dose schedule. A multiple dose s~heAl~le i9 one in which a primary course of vaccination may include 1 to 10 separate doses, followed by other doses ~Am; n; stered WO94/20138 215 6 719 PCT~S94/02~7 ~
at subsequent time intervals as required to maintain and or reinforce the imm~ne response, e.g., at 1 to 4 months for a second dose, and if needed, a subsequent dose(s) after several months.
The invention will be better understood by reference to the following examples, which are intended to merely illustrate the best mode now known for practicing the invention. The invention is not to be considered limited thereto, however.
Examples Example l: Identification of E~itope for EBV-Neutralizinq Antibody To identify the epitope for EBV-neutralizing antibody, the following recombinant plasmids were constructed. A 4.3 XhoII-~Ç~II DNA fragment cont~;n;ng the entire EBV gp350/220 coding ~nm~in (except the signal peptide) was subcloned from the pl~qm;~ pMA102 into the baculovirus expression vector pBlueBacHisC (Invitrogen), resulting in plasmid pBac-TTI350. This fragment contains the entire region of gp350/220 which i5 the protein present on the outer surface of EBV-infected cells. An NcoI fragment encoding the serine and threonine-rich sequences was deleted from pBac-TTI350 to generate plasmid pBac-TTI300. The NcoI fragment was recloned at the NcoI site of plasmid pBlue~ac~isC to generate pBac-TTI250. These manipulations employed E. coli strain Top 10 (Invitrogen). A synthetic DNA coding for the nine amino acids Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu was also introduced upstream of the se~uence coding for 66 kd protein. This peptide has been shown to be involved in me~i~ting EBV attachment to human B-cell receptor CR2.
Construction of such a protein will not only produce WO94/20138 ~ S67~ PCT~S94102637 neutralizing antibody but will also inhibit viral binding and entry into the B-cells.
A baculovirus transfer vector is used to replace the viral polyhedrin gene with the gene o~
interest by homologous recombination. Sequences which flank the polyhedrin gene in the wild-type genome are positioned 5' to 3' to the expression cassette on the transfer vector. Following cotransfection, homologous recombination between these sequences results in a recombinant ~irus with the gene of interest expressed under the control of the viral polyhedrin enhancer/promoter elements. The vector pBlueBacHisC used here also expresses galactosidase to provide a blue reporter for visual identification of blue recombinant plaques. The recombinant virus was produced and purified according to the method described in the Invitrogen m;3 n~
The expression of the gp350/220 sequence in insect cells derived from Spodoptera frugiperda ovarian cells (Sf9 Cells, Invitrogen) was confirmed by Western blot analysis in the following m~nn~r, Insect cells were infected with virus cont~ n ~ ng recombinant plasmid pBac-TTI350, pBac-TTI300 and pBac-TTI250, respectively. After three days, a lml sample of cells was L~mo~ed from each culture. As positive controls for molecular weights of 350 and 220 kd, l ml samples of Raji cells infected with EBV were also u~ed in the following test. The cells were pelleted and dissolved in lO0 ~l of T.~Qmm1 i buffer.
After boiling for 2 min, the samples were loaded on a lO~
SDS-polyacrylamide gel and electrophore~ed overnight at 70 volts. The proteins were transferred electrophoretically to a nitrocellulose membrane.
Nonspecific binding of the protein was blocked by treating the membrane with 5~ nonfat dry milk in TBST (lO
mM Tris, pH 8.0/l mM EDTA/0.05~ Tween-20). High-titer , WO94/20138 ~1 ~ 6 ~19 PCT~S94/02~7 EBV-;mm~ln~ human serum and a monoclonal EBV-neutralizing antibody to gp350/220 (DuPont, Boston, MA), respectively, were added to the blots and incubated for 1 hr, washed 3 times for 5 min each with TBST, and then incubated with anti-human IgG-alkaline phosphatase conjugate for 30 min.
After washing 3 times with TBST, the color was developed.
Cells infected with recombinant virus pBac-TTI350 showed two bands with molecular weights of 350 and 220 kd, with both EBV ;mmllne human serum and monoclonal EBV neutralizing antibody. The recombinant protein bands appeared in the same position as the protein bands from the Raji cells infected with EBV. No reaction was seen with cells infected with recombinant virus pBac-TTI300, from which the serine- and threonine-rich sequence of gp350/220 had been deleted. Because the TTI300 plasmid did not react, the serine- and threonine-rich sequence appears to be the likely epitope for neutralizing antibody. This result was further confirmed by ;mmllnoreaction of human serum and monoclonal antibody to cells infected with recombinant virus pBac-TTI250 which contains the serine- and threonine-rich sequences which has been deleted from pBac-TTI300. The size of the reactive protein from pBAC-TTI250 was 66 kd.
Example 2: Purification of Recombinant Proteins The vector pBl--~R~;8C contains the DNA
sequence below the translation start codon which produces a six-histidine peptide at the N-tPrm;n~l region of the expressed protein. This peptide has an affinity for the ProBond resin (Invitrogen) and thus allows one-step purification. For each of the two proteins, about 500 ml of insect cells Sf9 was grown at a density of 2 x 106 cells/ml in a 500 ml spinner ~lask. Cells were infected with high-titer viral stock of either the pBac-TTI250-infected virus (66 kd protein) or the pBac-TTI350-W094/20138 ~ S671~ PCT/US94/02637 infected virus (the 350/220 kd protein). Then the cells were grown for 3 days. The cells were pelleted by centrifugation and suspended in 20 mM sodium phosphate and 500 mM NaCl and lysed by sonication and centrifuged to remove cell debris. The recom~inant proteins were puri~ied from the supernatant through ProBond resin by the method described by Invitrogen. First, the 6-histidine end of the recombinant protein binds to the ProBond resin. Then the reco-mbinant protein is cleaved off by enterokinase applied to the column. This isolation method gave single protein bands (66 kd or 350/220 kd proteins) on SDS-polyacrylamide gel. The 350 and 220 kd bands were in the same position for recombinant and Raji-cell-derived proteins. About 5 mg of purified protein was obtained from each 500 ml of culture.
Because the 66 kd recombinant protein derived from gp350/220 is ;mml~noreactive with both the EBV lmml~n~
human serum and monoclonal antibody that neutralizes EBV
virus, this protein can be used to develop vaccine for EBV. In addition, because the 66 kd protein also has a nine-amino acid sequence for EBV attachment to B-cells, vaccines developed with this protein also should inhibit viral binding and entry into B-cells.
Expression in baculovirus provides several advantayes. While E. coli synthesize unglycosylated proteins, and yeast produce proteins which are differently glycosylated, proteins produced in baculovirus are glycosylated and have a glycosylation pattern similar to that resulting from expression in mAmm~lian cells. A further advantage i9 that much larger quantities of pure protein can be obtained from baculovirus than from mAmm~lian cells. Moreover, the expression of recombinant gp350/220 in m~mm~l ian cells is generally very unstable. Therefore, either the 66 kd or WO94/20138 21~ 6 ~ ~ 9 PCT~S94/02637 ~
the 350/220 kd protein produced in insect cells provides a more stable and efficient method of making purified vaccine protein.
Smaller proteins provide several advantages over large proteins for vaccine development. Smaller proteins permit the injection of more moles of epitope per weight or injection volume of vaccine. Smaller proteins may be processed more efficiently recombinantly and ;mmnnologically. Smaller proteins are less vulnerable to protease attack because they are less likely to have amino acid combinations for which the proteases are specific. Smaller proteins have fewer epitopes and elicit a more concentrated response.
Each of the publications and patents cited above are incorporated by reference.
While the invention has been described in connection with certain embo~;m~nts thereof, various modifications which may be apparent to one of skill in the art also fall within the scope of the invention as defined by the appended claims. The scope of the invention, therefore, should be det~rm; n~ not with reference to the above description, but should instead be det~rm;ne~ with reference to the appended claims, along with the full scope of e~uivalents to which such claims are entitled.
Claims (27)
1. A substantially pure polypeptide consisting essentially of the 66 kd serine- and threonine-rich portion of gp350/220 of EBV or fragments thereof capable of eliciting EBV-neutralizing antibodies in a mammal.
2. A glycosylated polypeptide of claim 1.
3. A vaccine composition comprising an immunogenic amount of a polypeptide of claim 2 admixed with a pharmaceutically acceptable carrier.
4. A method of protecting a mammal from EBV
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 2 admixed with a pharmaceutically acceptable carrier.
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 2 admixed with a pharmaceutically acceptable carrier.
5. A nucleic sequence encoding the polypeptide of claim 1.
6. An expression vector comprising a nucleic acid sequence encoding a polypeptide of claim 1 and expression control sequences that are operably linked to said nucleic acid and effective in directing expression of said nucleic acid in a cell.
7. A cell containing an expression vector of claim 6.
8. A method of producing a polypeptide comprising growing a cell of claim 7 under conditions that permit the production of said polypeptide.
9. A vaccine composition comprising an immunogenic amount of the polypeptide of claim 1 admixed with a pharmaceutically acceptable carrier.
10. A method of protecting a mammal from EBV
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 1 admixed with a pharmaceutically acceptable carrier.
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 1 admixed with a pharmaceutically acceptable carrier.
11. A substantially pure polypeptide for eliciting EBV-neutralizing antibodies in a mammal and inhibiting EBV binding and entry into B-cells, the polypeptide consisting essentially of: a 66 kd serine-and threonine-rich portion of gp350/220 of the EBV or fragments thereof; and a peptide consisting of the sequence Glu-Asp-Pro-Gly-Phe-Phe-Asn-Val-Glu adjacent to the amino-terminus of the 66 kd portion.
12. A method of protecting a mammal from EBV
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 11 admixed with a pharmaceutically acceptable carrier.
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 11 admixed with a pharmaceutically acceptable carrier.
13. A glycosylated polypeptide of claim 11.
14. A method of protecting a mammal from EBV
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 13 admixed with a pharmaceutically acceptable carrier.
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claim 13 admixed with a pharmaceutically acceptable carrier.
15. A vaccine composition comprising an immunogenic amount of a polypeptide of claim 13 admixed with a pharmaceutically acceptable carrier.
16. A nucleic sequence encoding the polypeptide of claim 11.
17. An expression vector comprising a nucleic acid sequence encoding a polypeptide of claim 11 and expression control sequences that are operably linked to said nucleic acid and effective in directing expression of said nucleic acid in a cell.
18. A cell containing an expression vector of claim 17.
19. A method of producing a polypeptide comprising growing a cell of claim 18 under conditions that permit the production of said polypeptide.
20. A vaccine composition comprising an immunogenic amount of a polypeptide of claim 11 admixed with a pharmaceutically acceptable carrier.
21. A method of producing a substantially pure EBV gp350/220 protein, said method comprising subcloning the complete EBV gp350/220 gene into the baculovirus expression vector pBlueBacHisC to form a plasmid pBac-TTI350 which comprises the EBV gp350/220 gene and a 6-histidine peptide, using the plasmid pBac-TTI350 to replace a gene in a virus with DNA encoding at least the EBV gp350/220 protein and the 6-histidine peptide, transfecting insect cells with the virus containing the EBV gp350/220 gene, harvesting transfected insect cells, separating the EBV gp350/220 protein from the transfected insect cells, purifying the EBV gp350/220 protein on a column whose resin has an affinity for a 6-histidine peptide, and separating EBV gp350/220 protein from the 6-histidine peptide.
22. The protein produced by the method of claim 21.
23. The method of claim 21 wherein the EBV
gp350/220 gene lacks the amino terminus sequence encoding for the signal protein.
gp350/220 gene lacks the amino terminus sequence encoding for the signal protein.
24. The protein produced by the method of claim 23.
25. A method of producing a substantially pure EBV gp350/220 protein, said method utilizing baculovirus comprising genes encoding EBV gp350/220 and a 6-histidine polypeptide, said method comprising:
transfecting insect cells with said baculovirus, harvesting transfected insect cells, separating the EBV gp350/220 protein and the 6-histidine polypeptide from the transfected insect cells, and purifying the EBV gp350/220 protein and the 6-histidine polypeptide on a column whose resin has an affinity for the 6-histidine peptide.
transfecting insect cells with said baculovirus, harvesting transfected insect cells, separating the EBV gp350/220 protein and the 6-histidine polypeptide from the transfected insect cells, and purifying the EBV gp350/220 protein and the 6-histidine polypeptide on a column whose resin has an affinity for the 6-histidine peptide.
26. The EBV gp350/220 protein produced by the method of claim 25.
27. A method of protecting a mammal from EBV
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claims 22, 24 or 26 admixed with a pharmaceutically acceptable carrier.
infection comprising administering to said mammal an immunologically effective dose of a vaccine composition comprising an immunogenic amount of a polypeptide of claims 22, 24 or 26 admixed with a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3118693A | 1993-03-12 | 1993-03-12 | |
US08/031,186 | 1993-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2156719A1 true CA2156719A1 (en) | 1994-09-15 |
Family
ID=21858082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002156719A Abandoned CA2156719A1 (en) | 1993-03-12 | 1994-03-11 | Recombinant epstein-barr virus protein and its use in vaccine |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0690917A4 (en) |
JP (1) | JPH08507442A (en) |
KR (1) | KR960700749A (en) |
AU (1) | AU681131B2 (en) |
CA (1) | CA2156719A1 (en) |
WO (1) | WO1994020138A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001259306A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
GB0210682D0 (en) | 2002-05-09 | 2002-06-19 | Glaxosmithkline Biolog Sa | Novel use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0173254B1 (en) * | 1984-08-23 | 1991-07-24 | Hans Joachim Wolf | Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens |
-
1994
- 1994-03-11 WO PCT/US1994/002637 patent/WO1994020138A1/en not_active Application Discontinuation
- 1994-03-11 KR KR1019950703810A patent/KR960700749A/en not_active Application Discontinuation
- 1994-03-11 AU AU64045/94A patent/AU681131B2/en not_active Ceased
- 1994-03-11 CA CA002156719A patent/CA2156719A1/en not_active Abandoned
- 1994-03-11 EP EP94911554A patent/EP0690917A4/en not_active Withdrawn
- 1994-03-11 JP JP6520327A patent/JPH08507442A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU6404594A (en) | 1994-09-26 |
JPH08507442A (en) | 1996-08-13 |
EP0690917A4 (en) | 1996-05-22 |
KR960700749A (en) | 1996-02-24 |
AU681131B2 (en) | 1997-08-21 |
WO1994020138A1 (en) | 1994-09-15 |
EP0690917A1 (en) | 1996-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110279855B (en) | Novel genetic engineering vaccine of porcine Seneca virus, preparation method and application thereof | |
WO1991002536A1 (en) | Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders | |
CA2088599A1 (en) | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system | |
JP2005333990A (en) | Gp350/220 non-splicing variant | |
WO1998028004A1 (en) | Hepatitis delta particle containing a fusion protein immunogen | |
CA2156719A1 (en) | Recombinant epstein-barr virus protein and its use in vaccine | |
US20130064844A1 (en) | Non-splicing variants of gp350/220 | |
US5650313A (en) | Ubiquitin conjugating enzymes 8 and 9 | |
WO1998015289A9 (en) | Proteins of kaposi's sarcoma associated herpesvirus | |
WO1998015289A1 (en) | Proteins of kaposi's sarcoma associated herpesvirus | |
US6277380B1 (en) | Measles virus mutant antigen | |
CA2156416C (en) | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus | |
WO1998028420A1 (en) | Human parotid secretory protein | |
WO1994016062A1 (en) | Complement regulatory proteins of herpesvirus saimiri |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |